Ocriplasmin is Safe & Efficacious for patients with Vitreous
A Study was conducted to estimate the efficacy and safety of ocriplasmin for patients with vitreous macular traction (VMT) that concluded it to be efficacious.

Statistical analysis was conducted by R software version 3.6.3. Results in proportion with 95% confidence interval (CI) were calculated by means of Freeman–Tukey variant of arcsine square transformation.

--The pooling results indicated the overall complete release rate was 50%.

--For VMT patients younger than 65 years old, with smaller adhesion size of VMT (less than 1500 microm), phakic eyes, with macular hole (MH) and subretinal fluid (SRF), while without epiretinal membrane (ERM), ocriplasmin could achieve much higher complete release rates than those under opposite conditions.

--The general nonsurgical closure rate of MH was 34%, and it was positively correlated with the MH size. The visual improvement rate was 45%, and it was higher for patients with VMT resolution (59%).

--The secondary pars plana vitrectomy (PPV) rate for patients without MH closure or VMT resolution was about 31%.

--The incidence of MH progression was 10%, and other severe adverse events such as endophthalmitis, retinal detachment and retinal tear were relatively rare.

In conclusion, Ocriplasmin is an effective, dependable, and reasonably safe treatment for VMT. Patients younger than 65 years old, with smaller adhesion sizes (less than 1500 microm), phakic eyes, MH and SRF, but no ERM, were the best prospects.

Source: https://onlinelibrary.wiley.com/doi/10.1111/aos.14867?af=R